Literature DB >> 19339977

Molecular mechanisms of mTOR-mediated translational control.

Xiaoju Max Ma1, John Blenis.   

Abstract

The process of translation requires substantial cellular resources. Cells have therefore evolved complex mechanisms to control overall protein synthesis as well as the translation of specific mRNAs that are crucial for cell growth and proliferation. At the heart of this process is the mammalian target of rapamycin (mTOR) signalling pathway, which senses and responds to nutrient availability, energy sufficiency, stress, hormones and mitogens to modulate protein synthesis. Here, we highlight recent findings on the regulators and effectors of mTOR and discuss specific cases that serve as paradigms for the different modes of mTOR regulation and its control of translation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339977     DOI: 10.1038/nrm2672

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  122 in total

Review 1.  eIF4A: the godfather of the DEAD box helicases.

Authors:  George W Rogers; Anton A Komar; William C Merrick
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

Review 2.  EJCs at the heart of translational control.

Authors:  Hervé Le Hir; Bertrand Séraphin
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

Review 3.  TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals.

Authors:  N S Cutler; J Heitman; M E Cardenas
Journal:  Mol Cell Endocrinol       Date:  1999-09-10       Impact factor: 4.102

Review 4.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Authors:  David J Kwiatkowski; Brendan D Manning
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

5.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Authors:  David Shahbazian; Philippe P Roux; Virginie Mieulet; Michael S Cohen; Brian Raught; Jack Taunton; John W B Hershey; John Blenis; Mario Pende; Nahum Sonenberg
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

Review 6.  Signalling by CD95 and TNF receptors: not only life and death.

Authors:  C Magnusson; D L Vaux
Journal:  Immunol Cell Biol       Date:  1999-02       Impact factor: 5.126

7.  Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.

Authors:  A J Waskiewicz; J C Johnson; B Penn; M Mahalingam; S R Kimball; J A Cooper
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

8.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

9.  A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

Authors:  Andrew M Arsham; Jessica J Howell; M Celeste Simon
Journal:  J Biol Chem       Date:  2003-05-30       Impact factor: 5.157

Review 10.  Tor signalling in bugs, brain and brawn.

Authors:  Estela Jacinto; Michael N Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

View more
  1136 in total

1.  The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease.

Authors:  Xiaoying Lian; Xiaoyuan Wu; Zhongxin Li; Yingjie Zhang; Kangkang Song; Guangyan Cai; Qinggang Li; Shupeng Lin; Xiangmei Chen; Xue-Yuan Bai
Journal:  Br J Pharmacol       Date:  2019-01-10       Impact factor: 8.739

2.  Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.

Authors:  Paola Castagnino; Devashish Kothapalli; Elizabeth A Hawthorne; Tina Xu; Richard K Assoian
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-05-10       Impact factor: 3.072

3.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

4.  Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

Authors:  E Norsted Gregory; S Codeluppi; J A Gregory; J Steinauer; C I Svensson
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

5.  Targeted immunosuppression: no longer naïve.

Authors:  Robert S Hagan; Jonathan D Powell
Journal:  Clin Immunol       Date:  2011-10-25       Impact factor: 3.969

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.

Authors:  Stuti Agarwal; Catherine M Bell; Shirley M Taylor; Richard G Moran
Journal:  Mol Cancer Res       Date:  2015-09-18       Impact factor: 5.852

8.  Bifenthrin causes transcriptomic alterations in mTOR and ryanodine receptor-dependent signaling and delayed hyperactivity in developing zebrafish (Danio rerio).

Authors:  Daniel F Frank; Galen W Miller; Danielle J Harvey; Susanne M Brander; Juergen Geist; Richard E Connon; Pamela J Lein
Journal:  Aquat Toxicol       Date:  2018-04-18       Impact factor: 4.964

Review 9.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

10.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.